Format

Send to

Choose Destination
Cancer Med. 2017 Jul;6(7):1807-1816. doi: 10.1002/cam4.1128. Epub 2017 Jun 22.

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.

Author information

1
Department of Hematology, Aalborg University Hospital, DK-9000, Aalborg, Denmark.
2
Department of Hematology, Rigshospitalet, University of Copenhagen, DK-2100, Copenhagen, Denmark.
3
Department of Hematology and the Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, DK-5000, Odense C, Denmark.
4
Department of Hematology, Aarhus University Hospital, DK-8000, Aarhus, Denmark.
5
Department of Hematology, Regional Hospital West Jutland, DK-7500, Holstebro, Denmark.
6
Department of Hematology, Roskilde Hospital, DK-4000, Roskilde, Denmark.
7
Department of Hematology, Herlev Hospital, DK-2730, Herlev, Denmark.
8
Department of Hematology, Vejle Hospital, DK-7100, Vejle, Denmark.
9
Department of Hematology, Esbjerg Hospital, DK-6700, Esbjerg, Denmark.

Abstract

To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.

KEYWORDS:

Comorbidity; international classification of diseases; multiple myeloma; prognosis; survival

PMID:
28639741
PMCID:
PMC5504337
DOI:
10.1002/cam4.1128
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center